Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1362Gemcitabine 1235Bevacizumab 1226Paclitaxel 1214Radiotherapy 1176Docetaxel 1080pembrolizumab 1029Oxaliplatin 936Capecitabine 902Fluorouracil 833Rituximab 729Doxorubicin 684Nivolumab 679Dexamethasone 667Etoposide 660Irinotecan 622Leucovorin 576Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 470Cytarabine 467Magnetic Resonance Spectroscopy 461Filgrastim 446Prednisone 433Specimen Handling 411Lenalidomide 410Vincristine 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × TLC 388 × Clear all
NCT02457273 2019-04-03

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

National Health Research Institutes, Taiwan

Phase 2 Completed
23 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 2 Terminated
29 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡